内容摘要：“Almost every chronic health symptom that Western medicine addresses is the result of our cells being beleaguered by how we’ve come to live,” Means said in a 2024 book co-written with her brother.

“Almost every chronic health symptom that Western medicine addresses is the result of our cells being beleaguered by how we’ve come to live,” Means said in a 2024 book co-written with her brother.

Kiefer was at a medical appointment the day fire engulfed her neighborhood and her children couldn’t find Aggie — who was prone to hiding — when they tried to rescue her.“The one thing my mom asked was: ‘Did you get Aggie?” Carolyn recalls.

Many pet owners struggled to reach their domesticated animals during the frantic rush to evacuate from the Palisades wildfire in January.Aggie, who is about 5 years old, was gifted to Katherine Kiefer by a friend during the COVID-19 pandemic. Social media users have been so touched by the pair’s reunion video that many have been asking for daily updates. The family’s $30,000 GoFundMe campaign for Aggie’s vet bills had topped $21,000 by Tuesday afternoon.The cat has undergone several blood transfusions and is now seeing a specialist.

“She was basically skin and bone, and in a state of absolute starvation,” Carolyn said.The family will officially be reunited with Aggie when she is released from the hospital Thursday. Kiefer said she’s anxiously waiting, and she has a message for other pet owners: “Don’t underestimate cats,” she said.

ALBUQUERQUE, N.M. (AP) — Commissioners in a rural New Mexico county say pets are being snatched from front yards and livestock are being maimed and killed by endangered

that seem to have no fear of humans, prompting them to declare a state of emergency.The new test, from Fujirebio Diagnostics, Inc., identifies a sticky brain plaque, known as beta-amyloid, that is a key marker for Alzheimer’s. Previously, the only FDA-approved methods for detecting amyloid were invasive tests of spinal fluid or expensive PET scans.

The lower costs and convenience of a blood test could also help expand use of two new drugs, Leqembi and Kisunla, which have been shown to slightly slow the progression of Alzheimer’s by clearing amyloid from the brain. Doctors are required to test patients for the plaque before prescribing the drugs, which require regular IV infusions.“Today’s clearance is an important step for Alzheimer’s disease diagnosis, making it easier and potentially more accessible for U.S. patients earlier in the disease,” said Dr. Michelle Tarver, of FDA’s center for devices.

A number of specialty hospitals and laboratories have already developed their own in-house tests for amyloid in recent years. But those tests aren’t reviewed by the FDA and generally aren’t covered by insurance. Doctors have also had little data to judge which tests are reliable and accurate, leading to an unregulated marketplace that some have called a “wild west.”Several larger diagnostic and drug companies are also developing their own tests for FDA approval, including Roche, Eli Lilly and C2N Diagnostics.